Browse by author
Lookup NU author(s): Professor Margaret Bassendine,
Dr Raymond Barry
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background/Aims: The antiviral agent amantadine may have activity against the hepatitis C virus. To determine whether the combination of interferon-alpha plus amantadine was more effective than interferon monotherapy we conducted a multicentre clinical trial in untreated patients with chronic hepatitis C infection. Methods: We performed a pilot study in two centres (36 patients) to determine the number needed for a statistically significant clinical trial and then conducted a multicentre, randomized controlled clinical trial involving 14 centres and 143 patients. Results: There was no significant difference in sustained response rates in patients receiving interferon and amantadine compared to those receiving interferon alone. The on treatment response rate at 3 months was 65% on combination vs. 49% on interferon alone (P = 0.05) while the sustained response was 18 and 15%, respectively. Conclusions: Combination therapy with interferon plus amantadine does not lead to a significant increase in sustained response rates when compared to interferon monotherapy. (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
Author(s): Bassendine MF; Barry R; Caronia S; Mills P; Naoumov NV; Fox R; Lowes J; Hollanders D; Murray-Lyon L; Irving WL; Goldin RD; Foster GR; behalf UK Amantadine Study Grp
Publication type: Article
Publication status: Published
Journal: Journal of Hepatology
ISSN (print): 0168-8278
ISSN (electronic): 1600-0641
Publisher: Elsevier B.V.
Altmetrics provided by Altmetric